State of New Jersey Common Pension Fund D’s Fate Therapeutics FATE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-118,540
Closed -$1.2M 1730
2022
Q4
$1.2M Buy
118,540
+39,324
+50% +$739K ﹤0.01% 1626
2022
Q3
$1.77M Sell
79,216
-19,127
-19% -$553K 0.01% 1572
2022
Q2
$2.44M Buy
98,343
+22,085
+29% +$609K 0.01% 1051
2022
Q1
$2.96M Buy
76,258
+25,018
+49% +$969K 0.01% 1041
2021
Q4
$3M Buy
51,240
+3,245
+7% +$184K 0.01% 1091
2021
Q3
$2.85M Sell
47,995
-248
-0.5% -$19.5K 0.01% 1174
2021
Q2
$4.19M Buy
48,243
+4,473
+10% +$360K 0.01% 827
2021
Q1
$3.61M Sell
43,770
-1,237
-3% -$119K 0.01% 924
2020
Q4
$4.09M Sell
45,007
-20,072
-31% -$1.25M 0.01% 817
2020
Q3
$2.6M Sell
65,079
-1,937
-3% -$67.6K 0.01% 975
2020
Q2
$2.3M Buy
+67,016
New +$2M 0.01% 1151
2019
Q4
Sell
-106,800
Closed -$1.66M 1625
2019
Q3
$1.66M Buy
+106,800
New +$2.05M 0.01% 1486

Other funds holding FATE

State of New Jersey Common Pension Fund D's FATE Position: Q1 2023 in Review

State of New Jersey Common Pension Fund D sold out of Fate Therapeutics (FATE) in Q1 2023, closing a stake of 118,540 shares — an estimated $1.2M sold.

State of New Jersey Common Pension Fund D first reported a position in FATE in Q3 2019 and held it in 12 quarters. The position peaked at $4.19M in Q2 2021. 181 funds tracked by Wall St. Rank hold FATE as of Q1 2023.

  • State of New Jersey Common Pension Fund D reported no remaining Fate Therapeutics position as of Q1 2023 after selling out during the quarter.
  • State of New Jersey Common Pension Fund D sold 118,540 Fate Therapeutics shares in Q1 2023, an estimated $1.2M.
  • State of New Jersey Common Pension Fund D first reported a position in Fate Therapeutics in Q3 2019 and held it in 12 quarters.
  • State of New Jersey Common Pension Fund D's Fate Therapeutics position peaked at $4.19M in Q2 2021.
  • 181 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2023.

Based on State of New Jersey Common Pension Fund D's 13F filing for Q1 2023, filed 26 Apr 2023.